CA-3E
16.11.2023 15:01:34 CET | Business Wire | Press release
Headquartered in Europe with a global reach, Chemycal’s suite of software and data solutions enable global enterprises to navigate the ever-evolving regulatory backdrop by making complex chemical and product management decisions in a more informed and confident manner. Chemycal supports the creation of safer and more sustainable products by providing essential compliance tools and intelligent information, including global regulatory news tracking and 360-degree monitoring of regulatory updates, that highlight the impact of local changes on a company’s global portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231113229200/en/
“Chemycal’s offerings cover critical aspects of a customer’s regulatory monitoring activities, from reporting real-time news to delivering actionable product-level insights,” said Greg Gartland, Chief Executive Officer of 3E. “Chemycal’s ability to help global corporations track and comply with increasingly complex regulations aligns with 3E’s purpose to enable a safer, more sustainable world. We look forward to introducing Chemycal’s industry-leading platform and content to our over 5,000 customers globally.”
Heightened regulatory pressures have led to growing customer demand for efficient and reliable compliance solutions. The combined content and coverage from 3E and Chemycal responds to this market need. Chemycal's broad monitoring and content coverage from more than 1,500 regulatory sources, alongside 3E's broad regulatory data and substance coverage, will provide enhanced global horizon scanning capabilities for clients.
Luca Mohammadi, Co-Founder and CTO of Chemycal, said, “We are thrilled to be joining 3E, a company that shares our vision for providing businesses with the vital data, intelligence, and tools to ensure their products can move safely through the value chain to protect people and the environment. Joining 3E will provide our customers an end-to-end suite of global monitoring products to realize our shared vision.”
“We’re excited to join 3E and bring our platforms to a larger audience,” added Lorenzo Zullo, Co-Founder and CEO of Chemycal. “We have found in 3E a leadership team with the necessary passion, scale and resources to further accelerate Chemycal’s impressive historical growth. We share the same vision to better support global industries to address emerging regulatory challenges. Coupling our scalable platform with 3E’s deep regulatory domain expertise creates a powerful combination, which will empower our customers to consistently achieve their compliance goals.”
Chemycal represents 3E’s third acquisition announcement since its separation from Verisk in March 2022.
Shearman & Sterling LLP served as the legal advisor to 3E. Cambrian served as the legal advisor to Chemycal.
About Chemycal
Founded in 2015, Chemycal is a global regulatory monitoring company, pairing advanced software and technology with domain expertise to aggregate chemical and product compliance data. Leveraging its worldwide network of 1,500 sources, the Company maintains a deep library of 35,000+ news summaries and 150,000+ substances and materials, keeping customers up to date with real-time developments relevant to their product portfolio via its advanced content management system and machine learning algorithms. Clients around the world trust Chemycal with the compliance of their products and the continuity of their businesses.
About 3E
For more than 35 years the world’s leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world’s largest chemical manufacturers, retailers and pharmaceutical companies. Learn more at www.3Eco.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231113229200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom